Abstract
Pulmonary surfactant protein A (SP-A) regulates the uptake and secretion of phospholipid by alveolar type II cells and is an important component of surfactant lipid aggregates. In an attempt to understand how specific structural domains of SP-A relate to the function of the protein, we used site-directed mutagenesis of the cDNA for SP-A and heterologous expression with baculovirus vectors. Synthesis of the wild type SP-A in insect cells resulted in a form of the protein in which proline residues were not hydroxylated and that is denoted SP-Ahyp. Three mutant SP-As with substitutions in the consensus sequences for glycosylation (SP-Ahyp,glc) to prevent N-linked oligosaccharide attachment at Asn1 and Asn187 were produced, individually and in tandem. The SP-Ahyp was glycosylated at both the Asn1 and Asn187 positions, demonstrated partial sulfhydryl-dependent oligomerization, and formed incomplete oligomers in solution. The SP-Ahyp and SP-Ahyp,glc bound to immobilized carbohydrate and to phospholipid liposomes and partially competed for occupancy of a plasma-membrane receptor for SP-A. The SP-Ahyp and the SP-Ahyp,glc were equally effective inhibitors of the secretion of surfactant lipids from isolated type II cells (IC50 = 0.5 microgram/ml) and aggregated phospholipid liposomes at 20 degrees C. All of the recombinant SP-As demonstrated markedly reduced aggregation of lipid at 37 degrees C. We conclude that the hydroxylation of proline residues is required for perfect oligomerization of SP-A and for thermal stability in the interaction with lipid. Furthermore, recombinant SP-A is able to inhibit the secretion of phospholipid from isolated type II cells and to aggregate lipid vesicles independent of the presence of N-linked carbohydrate or the site of glycosylation.
Highlights
From the $Cord and Taylor Laboratory for Lung Biochemistry, Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine and the $Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Health Sciences Center, Denuer, Colorado 80206
We examined lipid binding as a phenomenon distinct Ile5 for Val5 in theSP-AhYp*thwr' as found upon sequencing the from aggregation
23.2 2 2.4% of SP-AhYP sedimented with theliposomes at not requiredfor the covalent oligomerization of Surfactant protein A (SP-A)
Summary
The SP-AhYP and the SP-AhYp*SSwrcere lagen-like domain which is rich inhydroxyproline, a hydrophoeffective inhibitors of the secretion of surfactant lipids bic region (the putative phospholipid binding domain), and a from isolated type 11 cells (ICrn = 0.5 pg/ml) and aggre- carboxyl-terminal carbohydrate binding domain. For glycosylation altered; SP-Ahyp,TMS,P-AhYpwithglycosylation pre- tetradecanoylphorbol-13-acetate;m.o.i., multiplicityof infection; PAGE, vented by incubation of recombinant baculovirus infected cellswith polyacrylamide gel electrophoresis; PM, plasma membrane. In a few experitached carbohydrateis essential for lipid aggregation, receptor ments, 2.5% Manduca sexta hemolymph (a gift of John Law, University binding, or the inhibition of secretion of phospholipid from al- of Arizona) was addedt o the mediaas a source for insect transferrin to veolar type I1 cells. Tunicamycin was added at 5 pg/ml in some experiments to inhibit N-linkgedlycosylation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
